256 related articles for article (PubMed ID: 18676851)
21. Cotreatment with apicidin overcomes TRAIL resistance via inhibition of Bcr-Abl signaling pathway in K562 leukemia cells.
Park SJ; Kim MJ; Kim HB; Sohn HY; Bae JH; Kang CD; Kim SH
Exp Cell Res; 2009 Jul; 315(11):1809-18. PubMed ID: 19268463
[TBL] [Abstract][Full Text] [Related]
22. Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway.
Park SJ; Kim MJ; Kim HB; Sohn HY; Bae JH; Kang CD; Kim SH
Biochem Pharmacol; 2009 Apr; 77(8):1328-36. PubMed ID: 19426671
[TBL] [Abstract][Full Text] [Related]
23. Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8.
Häcker S; Dittrich A; Mohr A; Schweitzer T; Rutkowski S; Krauss J; Debatin KM; Fulda S
Oncogene; 2009 Sep; 28(35):3097-110. PubMed ID: 19597472
[TBL] [Abstract][Full Text] [Related]
24. The pleiotropic effect of TRAIL on tumor-like synovial fibroblasts from rheumatoid arthritis patients is mediated by caspases.
Audo R; Combe B; Coulet B; Morel J; Hahne M
Cell Death Differ; 2009 Sep; 16(9):1227-37. PubMed ID: 19407827
[TBL] [Abstract][Full Text] [Related]
25. Glycogen synthase kinase-3 inhibitors augment TRAIL-induced apoptotic death in human hepatoma cells.
Beurel E; Blivet-Van Eggelpoël MJ; Kornprobst M; Moritz S; Delelo R; Paye F; Housset C; Desbois-Mouthon C
Biochem Pharmacol; 2009 Jan; 77(1):54-65. PubMed ID: 18938143
[TBL] [Abstract][Full Text] [Related]
26. Enhancement of death receptor 4 mediated apoptosis and cytotoxicity in renal cell carcinoma cells by subtoxic concentrations of doxorubicin.
Jin X; Wu XX; Abdel-Muneem Nouh MA; Kakehi Y
J Urol; 2007 May; 177(5):1894-9. PubMed ID: 17437844
[TBL] [Abstract][Full Text] [Related]
27. TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes.
Guo L; Fan L; Pang Z; Ren J; Ren Y; Li J; Chen J; Wen Z; Jiang X
J Control Release; 2011 Aug; 154(1):93-102. PubMed ID: 21609741
[TBL] [Abstract][Full Text] [Related]
28. Involvement of tyrosine kinase p56/Lck in apoptosis induction by anticancer drugs.
Gruber C; Henkel M; Budach W; Belka C; Jendrossek V
Biochem Pharmacol; 2004 May; 67(10):1859-72. PubMed ID: 15130763
[TBL] [Abstract][Full Text] [Related]
29. Sensitization to the lysosomal cell death pathway by oncogene-induced down-regulation of lysosome-associated membrane proteins 1 and 2.
Fehrenbacher N; Bastholm L; Kirkegaard-Sørensen T; Rafn B; Bøttzauw T; Nielsen C; Weber E; Shirasawa S; Kallunki T; Jäättelä M
Cancer Res; 2008 Aug; 68(16):6623-33. PubMed ID: 18701486
[TBL] [Abstract][Full Text] [Related]
30. The PEA-15/PED protein protects glioblastoma cells from glucose deprivation-induced apoptosis via the ERK/MAP kinase pathway.
Eckert A; Böck BC; Tagscherer KE; Haas TL; Grund K; Sykora J; Herold-Mende C; Ehemann V; Hollstein M; Chneiweiss H; Wiestler OD; Walczak H; Roth W
Oncogene; 2008 Feb; 27(8):1155-66. PubMed ID: 17700518
[TBL] [Abstract][Full Text] [Related]
31. Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway.
Bortul R; Tazzari PL; Billi AM; Tabellini G; Mantovani I; Cappellini A; Grafone T; Martinelli G; Conte R; Martelli AM
Br J Haematol; 2005 Jun; 129(5):677-86. PubMed ID: 15916691
[TBL] [Abstract][Full Text] [Related]
32. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
Serra V; Markman B; Scaltriti M; Eichhorn PJ; Valero V; Guzman M; Botero ML; Llonch E; Atzori F; Di Cosimo S; Maira M; Garcia-Echeverria C; Parra JL; Arribas J; Baselga J
Cancer Res; 2008 Oct; 68(19):8022-30. PubMed ID: 18829560
[TBL] [Abstract][Full Text] [Related]
33. Downregulation of survivin and activation of caspase-3 through the PI3K/Akt pathway in ursolic acid-induced HepG2 cell apoptosis.
Tang C; Lu YH; Xie JH; Wang F; Zou JN; Yang JS; Xing YY; Xi T
Anticancer Drugs; 2009 Apr; 20(4):249-58. PubMed ID: 19174695
[TBL] [Abstract][Full Text] [Related]
34. The XIAP inhibitor Embelin enhances TRAIL-mediated apoptosis in malignant glioma cells by down-regulation of the short isoform of FLIP.
Siegelin MD; Gaiser T; Siegelin Y
Neurochem Int; 2009 Nov; 55(6):423-30. PubMed ID: 19409438
[TBL] [Abstract][Full Text] [Related]
35. Rapid and significant induction of TRAIL-mediated type II cells in apoptosis of primary salivary epithelial cells in primary Sjögren's syndrome.
Nakamura H; Kawakami A; Iwamoto N; Ida H; Koji T; Eguchi K
Apoptosis; 2008 Nov; 13(11):1322-30. PubMed ID: 18791828
[TBL] [Abstract][Full Text] [Related]
36. Enhancement of lexatumumab-induced apoptosis in human solid cancer cells by Cisplatin in caspase-dependent manner.
Wu XX; Kakehi Y
Clin Cancer Res; 2009 Mar; 15(6):2039-47. PubMed ID: 19276256
[TBL] [Abstract][Full Text] [Related]
37. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma.
Baumann P; Mandl-Weber S; Oduncu F; Schmidmaier R
Exp Cell Res; 2009 Feb; 315(3):485-97. PubMed ID: 19071109
[TBL] [Abstract][Full Text] [Related]
38. Insulin-like growth factor-1 delays Fas-mediated apoptosis in human neutrophils through the phosphatidylinositol-3 kinase pathway.
Himpe E; Degaillier C; Coppens A; Kooijman R
J Endocrinol; 2008 Oct; 199(1):69-80. PubMed ID: 18653623
[TBL] [Abstract][Full Text] [Related]
39. Hepatocyte growth factor prevents advanced glycation end products-induced injury and oxidative stress through a PI3K/Akt-dependent pathway in human endothelial cells.
Zhou YJ; Yang HW; Wang XG; Zhang H
Life Sci; 2009 Nov; 85(19-20):670-7. PubMed ID: 19778541
[TBL] [Abstract][Full Text] [Related]
40. Doxorubicin and selenium cooperatively induce fas signaling in the absence of Fas/Fas ligand interaction.
Li S; Zhou Y; Dong Y; Ip C
Anticancer Res; 2007; 27(5A):3075-82. PubMed ID: 17970047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
